vs

Side-by-side financial comparison of MEDIFAST INC (MED) and RAYONIER INC (RYN). Click either name above to swap in a different company.

RAYONIER INC is the larger business by last-quarter revenue ($117.5M vs $75.1M, roughly 1.6× MEDIFAST INC). On growth, MEDIFAST INC posted the faster year-over-year revenue change (-36.9% vs -81.9%). Over the past eight quarters, RAYONIER INC's revenue compounded faster (1.7% CAGR vs -34.4%).

Medifast, Inc. is an American nutrition and weight loss company based in Baltimore, Maryland. Medifast produces, distributes, and sells weight loss and health-related products through websites, multi-level marketing, telemarketing, and franchised weight loss clinics.

Rayonier Inc., headquartered in Wildlight, Florida is a timberland real estate investment trust ("REIT") with assets located in softwood timber growing regions in the United States and New Zealand. Its core business segments are timber and real estate.

MED vs RYN — Head-to-Head

Bigger by revenue
RYN
RYN
1.6× larger
RYN
$117.5M
$75.1M
MED
Growing faster (revenue YoY)
MED
MED
+45.0% gap
MED
-36.9%
-81.9%
RYN
Faster 2-yr revenue CAGR
RYN
RYN
Annualised
RYN
1.7%
-34.4%
MED

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
MED
MED
RYN
RYN
Revenue
$75.1M
$117.5M
Net Profit
$25.9M
Gross Margin
69.4%
41.9%
Operating Margin
-10.4%
23.0%
Net Margin
22.1%
Revenue YoY
-36.9%
-81.9%
Net Profit YoY
-92.1%
EPS (diluted)
$-1.64
$0.14

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
MED
MED
RYN
RYN
Q4 25
$75.1M
$117.5M
Q3 25
$89.4M
$177.5M
Q2 25
$105.6M
$106.5M
Q1 25
$115.7M
$82.9M
Q4 24
$119.0M
$650.5M
Q3 24
$140.2M
$124.1M
Q2 24
$168.6M
$99.6M
Q1 24
$174.7M
$113.7M
Net Profit
MED
MED
RYN
RYN
Q4 25
$25.9M
Q3 25
$-2.3M
$43.2M
Q2 25
$2.5M
$408.7M
Q1 25
$-772.0K
$-3.4M
Q4 24
$327.1M
Q3 24
$1.1M
$28.8M
Q2 24
$-8.2M
$1.9M
Q1 24
$8.3M
$1.4M
Gross Margin
MED
MED
RYN
RYN
Q4 25
69.4%
41.9%
Q3 25
69.5%
32.9%
Q2 25
72.6%
29.7%
Q1 25
72.8%
21.7%
Q4 24
74.1%
53.8%
Q3 24
75.4%
30.4%
Q2 24
73.2%
25.4%
Q1 24
72.8%
24.3%
Operating Margin
MED
MED
RYN
RYN
Q4 25
-10.4%
23.0%
Q3 25
-4.6%
23.5%
Q2 25
-1.0%
13.7%
Q1 25
-1.1%
0.1%
Q4 24
0.6%
47.7%
Q3 24
1.5%
15.2%
Q2 24
-4.7%
4.6%
Q1 24
4.5%
7.6%
Net Margin
MED
MED
RYN
RYN
Q4 25
22.1%
Q3 25
-2.5%
24.3%
Q2 25
2.3%
383.6%
Q1 25
-0.7%
-4.1%
Q4 24
45.1%
Q3 24
0.8%
23.2%
Q2 24
-4.8%
1.9%
Q1 24
4.8%
1.2%
EPS (diluted)
MED
MED
RYN
RYN
Q4 25
$-1.64
$0.14
Q3 25
$-0.21
$0.28
Q2 25
$0.22
$2.63
Q1 25
$-0.07
$-0.02
Q4 24
$0.08
$2.18
Q3 24
$0.10
$0.19
Q2 24
$-0.75
$0.01
Q1 24
$0.76
$0.01

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
MED
MED
RYN
RYN
Cash + ST InvestmentsLiquidity on hand
$167.3M
$842.9M
Total DebtLower is stronger
$845.3M
Stockholders' EquityBook value
$198.9M
$2.2B
Total Assets
$248.0M
$3.4B
Debt / EquityLower = less leverage
0.38×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
MED
MED
RYN
RYN
Q4 25
$167.3M
$842.9M
Q3 25
$173.5M
$919.6M
Q2 25
$162.7M
$892.3M
Q1 25
$164.6M
$216.2M
Q4 24
$162.3M
$303.1M
Q3 24
$170.0M
$51.9M
Q2 24
$163.5M
$120.2M
Q1 24
$156.4M
$142.1M
Total Debt
MED
MED
RYN
RYN
Q4 25
$845.3M
Q3 25
$845.1M
Q2 25
$844.9M
Q1 25
$1.0B
Q4 24
$1.0B
Q3 24
$1.3B
Q2 24
$1.4B
Q1 24
$1.4B
Stockholders' Equity
MED
MED
RYN
RYN
Q4 25
$198.9M
$2.2B
Q3 25
$214.7M
$2.3B
Q2 25
$216.0M
$2.3B
Q1 25
$211.0M
$1.9B
Q4 24
$210.1M
$1.8B
Q3 24
$207.3M
$1.8B
Q2 24
$205.3M
$1.8B
Q1 24
$211.0M
$1.8B
Total Assets
MED
MED
RYN
RYN
Q4 25
$248.0M
$3.4B
Q3 25
$268.2M
$3.5B
Q2 25
$269.3M
$3.5B
Q1 25
$280.0M
$3.4B
Q4 24
$284.2M
$3.5B
Q3 24
$291.2M
$3.5B
Q2 24
$293.5M
$3.5B
Q1 24
$302.8M
$3.6B
Debt / Equity
MED
MED
RYN
RYN
Q4 25
0.38×
Q3 25
0.37×
Q2 25
0.37×
Q1 25
0.55×
Q4 24
0.59×
Q3 24
0.72×
Q2 24
0.75×
Q1 24
0.74×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
MED
MED
RYN
RYN
Operating Cash FlowLast quarter
$-5.3M
$256.7M
Free Cash FlowOCF − Capex
$-6.6M
FCF MarginFCF / Revenue
-8.8%
Capex IntensityCapex / Revenue
1.8%
Cash ConversionOCF / Net Profit
9.91×
TTM Free Cash FlowTrailing 4 quarters
$1.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
MED
MED
RYN
RYN
Q4 25
$-5.3M
$256.7M
Q3 25
$12.1M
$116.2M
Q2 25
$-3.4M
$61.0M
Q1 25
$3.4M
$27.7M
Q4 24
$-4.9M
$261.6M
Q3 24
$9.1M
$66.2M
Q2 24
$13.1M
$55.3M
Q1 24
$7.3M
$52.3M
Free Cash Flow
MED
MED
RYN
RYN
Q4 25
$-6.6M
Q3 25
$10.8M
$99.9M
Q2 25
$-4.8M
Q1 25
$1.9M
Q4 24
$-7.2M
Q3 24
$7.7M
$42.2M
Q2 24
$11.1M
Q1 24
$5.4M
FCF Margin
MED
MED
RYN
RYN
Q4 25
-8.8%
Q3 25
12.0%
56.3%
Q2 25
-4.5%
Q1 25
1.6%
Q4 24
-6.1%
Q3 24
5.5%
34.0%
Q2 24
6.6%
Q1 24
3.1%
Capex Intensity
MED
MED
RYN
RYN
Q4 25
1.8%
Q3 25
1.5%
9.2%
Q2 25
1.3%
Q1 25
1.3%
Q4 24
1.9%
Q3 24
1.0%
19.3%
Q2 24
1.1%
Q1 24
1.1%
Cash Conversion
MED
MED
RYN
RYN
Q4 25
9.91×
Q3 25
2.69×
Q2 25
-1.36×
0.15×
Q1 25
Q4 24
0.80×
Q3 24
8.04×
2.30×
Q2 24
29.07×
Q1 24
0.88×
38.54×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

MED
MED

Segment breakdown not available.

RYN
RYN

Real Estate Segment$42.3M36%
Pacific Northwest Timber Segment$19.8M17%
Stumpage Pay As Cut$19.3M16%
Improved Development$14.8M13%
Nontimber$13.2M11%
License Revenue Primarily From Hunting$5.3M4%
Land Based Solutions$2.9M2%

Related Comparisons